Protocol Ledger

NCT04921384 · Phase III · COMPLETED

Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine

Interventional Phase III clinical trial protocol NCT04921384 sponsored by H. Lundbeck in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-29 Enrollment: 981 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04921384
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)981 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04921384
Protocol FieldVerified Registry Value
NCT IdentifierNCT04921384
Consolidated Lead SponsorH. Lundbeck
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment981 participants (ACTUAL)
Registered Start Date2021-05-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI